These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 33123166)

  • 1. Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect.
    Chen WC; Liu YB; Liu WF; Zhou YY; He HF; Lin S
    Front Immunol; 2020; 11():580378. PubMed ID: 33123166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour.
    Farzi A; Reichmann F; Holzer P
    Acta Physiol (Oxf); 2015 Mar; 213(3):603-27. PubMed ID: 25545642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New immunomodulatory role of neuropeptide Y (NPY) in Salmo salar leucocytes.
    González-Stegmaier R; Villarroel-Espíndola F; Manríquez R; López M; Monrás M; Figueroa J; Enríquez R; Romero A
    Dev Comp Immunol; 2017 Nov; 76():303-309. PubMed ID: 28676307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabolic syndrome in mice overexpressing neuropeptide Y in noradrenergic neurons.
    Ailanen L; Ruohonen ST; Vähätalo LH; Tuomainen K; Eerola K; Salomäki-Myftari H; Röyttä M; Laiho A; Ahotupa M; Gylling H; Savontaus E
    J Endocrinol; 2017 Jul; 234(1):57-72. PubMed ID: 28468933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptide y receptor selective ligands in the treatment of obesity.
    Kamiji MM; Inui A
    Endocr Rev; 2007 Oct; 28(6):664-84. PubMed ID: 17785427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropeptide Y in the noradrenergic neurones induces obesity and inhibits sympathetic tone in mice.
    Vähätalo LH; Ruohonen ST; Mäkelä S; Kovalainen M; Huotari A; Mäkelä KA; Määttä JA; Miinalainen I; Gilsbach R; Hein L; Ailanen L; Mattila M; Eerola K; Röyttä M; Ruohonen S; Herzig KH; Savontaus E
    Acta Physiol (Oxf); 2015 Apr; 213(4):902-19. PubMed ID: 25482272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropeptide Y (NPY).
    Groneberg DA; Folkerts G; Peiser C; Chung KF; Fischer A
    Pulm Pharmacol Ther; 2004; 17(4):173-80. PubMed ID: 15219262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NPY and receptors in immune and inflammatory diseases.
    Wheway J; Herzog H; Mackay F
    Curr Top Med Chem; 2007; 7(17):1743-52. PubMed ID: 17979783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer.
    Zhang L; Bijker MS; Herzog H
    Pharmacol Ther; 2011 Jul; 131(1):91-113. PubMed ID: 21439311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropeptide Y Y1 receptors mediate morphine-induced reductions of natural killer cell activity.
    Saurer TB; Ijames SG; Lysle DT
    J Neuroimmunol; 2006 Aug; 177(1-2):18-26. PubMed ID: 16766046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central control of feeding behavior by neuropeptide Y.
    Zimanyi IA; Fathi Z; Poindexter GS
    Curr Pharm Des; 1998 Aug; 4(4):349-66. PubMed ID: 10197048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between NPY and CRF in the amygdala to regulate emotionality.
    Sajdyk TJ; Shekhar A; Gehlert DR
    Neuropeptides; 2004 Aug; 38(4):225-34. PubMed ID: 15337374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropeptide Y and sleep.
    Dyzma M; Boudjeltia KZ; Faraut B; Kerkhofs M
    Sleep Med Rev; 2010 Jun; 14(3):161-5. PubMed ID: 20122859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation.
    Zhang L; Lee NJ; Nguyen AD; Enriquez RF; Riepler SJ; Stehrer B; Yulyaningsih E; Lin S; Shi YC; Baldock PA; Herzog H; Sainsbury A
    Diabetes Obes Metab; 2010 Jul; 12(7):591-603. PubMed ID: 20590734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double deletion of orexigenic neuropeptide Y and dynorphin results in paradoxical obesity in mice.
    Nguyen AD; Slack K; Schwarzer C; Lee NJ; Boey D; Macia L; Yulyaningsih E; Enriquez RF; Zhang L; Lin S; Shi YC; Baldock PA; Herzog H; Sainsbury A
    Neuropeptides; 2014 Jun; 48(3):143-51. PubMed ID: 24680736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropeptide-Y and Y-receptors in the autocrine-paracrine regulation of adrenal gland under physiological and pathophysiological conditions (Review).
    Spinazzi R; Andreis PG; Nussdorfer GG
    Int J Mol Med; 2005 Jan; 15(1):3-13. PubMed ID: 15583821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of neuropeptide Y for the neuroimmune crosstalk.
    Bedoui S; Kawamura N; Straub RH; Pabst R; Yamamura T; von Hörsten S
    J Neuroimmunol; 2003 Jan; 134(1-2):1-11. PubMed ID: 12507767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological and Therapeutic Roles of Neuropeptide Y on Biological Functions.
    Shende P; Desai D
    Adv Exp Med Biol; 2020; 1237():37-47. PubMed ID: 31468359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Over-Expression of Neuropeptide Y in Hypothalamic Paraventricular Nucleus Contributes to Adipose Tissue Insulin Resistance Partly via the Y5 Receptor.
    Long M; Zhou J; Li D; Zheng L; Xu Z; Zhou S
    PLoS One; 2015; 10(5):e0126714. PubMed ID: 25993471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs.
    Levens NR; Della-Zuana O
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1198-204. PubMed ID: 14649211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.